Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.

Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr.

J Hematol Oncol. 2010 Mar 11;3:9. doi: 10.1186/1756-8722-3-9.

2.

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.

Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG.

Int J Gynecol Cancer. 2010 Jul;20(5):772-80.

PMID:
20973267
3.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.

Steffensen KD, Waldstrøm M, Pallisgård N, Lund B, Bergfeldt K, Wihl J, Keldsen N, Marth C, Vergote I, Jakobsen A.

Int J Gynecol Cancer. 2013 Jan;23(1):73-80. doi: 10.1097/IGC.0b013e3182775fae.

PMID:
23211422
4.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; ASSIST-1 Study Group.

Eur J Cancer. 2009 Sep;45(13):2324-32. doi: 10.1016/j.ejca.2009.05.016. Epub 2009 Jun 8.

PMID:
19515553
5.

Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.

Ichikawa R, Torii Y, Oe S, Kawamura K, Kato R, Hasegawa K, Udagawa Y.

Arch Gynecol Obstet. 2014 Nov;290(5):979-84. doi: 10.1007/s00404-014-3268-7. Epub 2014 May 6.

PMID:
24798935
6.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
7.

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.

Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykiotis C, Pectasides E, Psyrri A, Koumarianou A, Gaglia A, Gouveris P, Economopoulos T.

Gynecol Oncol. 2008 Jan;108(1):47-52. Epub 2007 Oct 25.

PMID:
17915300
8.

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.

Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C.

Int J Gynecol Cancer. 2009 Aug;19(6):1137-41. doi: 10.1111/IGC.0b013e3181a8b938.

PMID:
19820382
9.

Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer.

Tas F, Derin D, Guney N, Aydiner A, Topuz E.

Int J Clin Oncol. 2008 Aug;13(4):330-4. doi: 10.1007/s10147-007-0757-8. Epub 2008 Aug 15.

PMID:
18704633
10.

Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.

Karaoglu A, Arslan UY, Ozkan M, Kalender ME, Alici S, Coskun U, Gumus M, Celenkoglu G, Er O, Sevinc A, Buyukberber S, Alkis N, Benekli M; Anatolian Society of Medical Oncology.

Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):63-6.

11.

A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.

Tas F, Guney N, Derin D, Aydiner A, Topuz E.

Int J Clin Oncol. 2008 Apr;13(2):156-60. doi: 10.1007/s10147-007-0740-4. Epub 2008 May 8.

PMID:
18463961
12.

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J.

Cochrane Database Syst Rev. 2013 Jul 9;(7):CD006910. doi: 10.1002/14651858.CD006910.pub2. Review.

PMID:
23835762
13.

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.

Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.

PMID:
25670764
14.

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.

Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD.

Gynecol Oncol. 2016 Feb;140(2):210-4. doi: 10.1016/j.ygyno.2015.11.031. Epub 2015 Nov 28.

15.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G.

J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.

16.
17.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
18.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.

Ann Oncol. 2012 May;23(5):1185-9. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5.

PMID:
21976386
19.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.

PMID:
22987083
20.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.

PMID:
24637997

Supplemental Content

Support Center